… effective quadrivalent vaccine is a major breakthrough in HPV research. Indeed, the vaccine
… this review that this quadrivalent vaccine is not the ideal vaccine for developing countries …

… vaccine against cervical cancer caused by vaccine HPV types. Phase III trials using a cervical
cancer … acquisition of infection to the development of cancer often exceeds 20 years, and …

… cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine
… /18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18. …

… There is a continued need for screening in vaccinated women for CIN and cervical cancer
… by gardasil account for only 70% of cervical cancers. However, screening intervals may be …

… In terms of the latter, the benefits of a quadrivalent vaccine are to some extent underestimated
in this analysis. In terms of the former, although one study to date has conducted a …

… of several decades from infection to cancer, we will need to … data for the quadrivalent vaccine
showing excellent efficacy … cancers is largely in the developing world, where for cervical …

… Gardasil, a quadrivalent anti-HPV vaccine, was approved by the FDA in June 2006 and is
indicated in females 9–26 years of age for the prevention of cervical cancer caused by HPV …

… Based on these European figures, our results suggest the quadrivalent HPV vaccine to
be likely cost effective when added to the current cervical cancer screening under base case …

… a quadrivalent HPV recombinant prophylactic vaccine represents the first time in history that
primary prevention of these cancers is … HPV subtypes in cervical cancers has been the most …

… , and a substantial proportion of cervical intraepithelial neoplasia … the effect of quadrivalent
HPV (qHPV) vaccination on incidence … vaccination program against invasive cervical cancer. …